Unraveling the Market Potential: PARP Inhibitors Forecast By 2022 to 2026

BySanket Badgujar
PARP Inhibitors Market

The PARP Inhibitors Market is predicted to grow to US$ 5.51 billion by 2022. Due to the increasing demand for sophisticated targeted therapy for the treatment of chronic illnesses like cancer, the market is growing. The market for PARP inhibitors is predicted to surpass US$ 8.43 billion during the projection period of 2022 to 2026, according to Future Market Insights (FMI). A fantastic CAGR of 11.2% will drive this expansion.

Since the prevalence of breast cancer is much greater in these nations and PARP inhibitors are more effective than other cancer treatment alternatives, the market for these drugs is anticipated to grow significantly over the forecast period.

Get Your Report Sample To Gain Comprehensive Insights! https://www.futuremarketinsights.com/reports/sample/rep-gb-3197

“The unique ability of PARP inhibitors to improve progression-free survival in ovarian and breast cancer patients is expected to generate extensive traction for the market, thereby propelling the growth of the global PARP inhibitors market over the forecast period.”

Key Takeaways of PARP Inhibitors Market Study:

  • Olaparib, with various expanded approvals for the treatment of ovarian cancer, breast cancer, and pancreatic cancer, and rapid increase in potential patient pool, contributed to the dominance of the segment by drug in 2021, and will continue to do so during the forecast period.
  • PARP inhibitors are regarded as a new standard of care for ovarian cancer after first-line platinum chemotherapy. Adoption of PARP inhibitors for ovarian cancer treatment has surged, and the trend is expected to continue during the forecast period, owing to the ability of PARP inhibitors to induce ovarian cancer patients into remission for longer periods of time as compared to any other marketed therapy.
  • With a strong pipeline, significant number of PARP inhibitors are expected to go for approval through the new drug application (NDA) process and for expanded approval to treat various types of cancers.

Strategic Acquisitions & Collaborations by Key Players to Widen Regional Presence:

All marketed PARP inhibitors are under patent, and with no generic launch in sight till 2027, the market is expected to remain consolidated till the second half of this decade. Key players in the PARP inhibitors market are undergoing major collaborative efforts, mergers, and acquisitions in order to expand their regional product offerings.

For example, in January 2022, GlaxoSmithKline plc acquired TESARO Inc., an oncology-focused biopharmaceutical company with a marketed PARP inhibitor named Zejula (Niraparib).

Key Companies Profiled:

  • AstraZeneca
  • GlaxoSmithKline
  • Merck Co. & Inc
  • GlaxoSmithKline plc
  • AbbVie Inc
  • Clovis Oncology
  • Medivation
  • Johnson & Johnson Services, Inc
  • Pfizer Inc.
  • Repare Therapeutics, Inc.
  • Genentech, Inc.
  • Artios Pharma
  • Repare Therapeutics Inc.
  • Sierra Oncology, Inc.
  • KaryopharmTherapeutics Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.

PARP Inhibitors Market by Category:

By Drug Type:

  • Olaparib
  • Niraparib
  • Rucaparib
  • Talazoparib

By Indication:

  • Ovarian Cancer
  • Breast Cancer
  • Prostate Cancer
  • Pancreatic Cancer

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies